PUBLISHER: The Business Research Company | PRODUCT CODE: 1769625
PUBLISHER: The Business Research Company | PRODUCT CODE: 1769625
Insulin aspart is a rapid-acting insulin analog used to manage blood glucose levels in individuals with diabetes. It begins to act within 10 to 20 minutes following injection, peaks between 1 to 3 hours, and remains effective for approximately 3 to 5 hours. This fast action makes insulin aspart suitable for controlling post-meal blood sugar spikes, thereby improving overall glycemic regulation.
The insulin aspart market research report is one of a series of new reports from The Business Research Company that provides insulin aspart market statistics, including insulin aspart industry global market size, regional shares, competitors with an insulin aspart market share, detailed insulin aspart market segments, market trends and opportunities, and any further data you may need to thrive in the insulin aspart industry. This insulin aspart market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The insulin aspart market size has grown strongly in recent years. It will grow from $3.37 billion in 2024 to $3.60 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historical period was supported by an increasing global diabetic population, enhanced awareness about managing the disease, wider use of advanced insulin delivery methods, higher global healthcare spending, and a notable shift towards faster-acting insulin therapies.
The insulin aspart market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. Key factors driving this projected growth include more funding in diabetes-related R&D, a rising elderly population, improvements in healthcare infrastructure, an upsurge in type 2 diabetes cases, and a growing trend toward tailored diabetes care solutions. Key market trends anticipated during this period include enhancements in insulin formulation science, integration with smart insulin administration technologies, breakthroughs in continuous glucose monitoring, the rise of personalized medicine, and progress in digital healthcare tools.
The increasing prevalence of diabetes is anticipated to drive the growth of the insulin aspart market. Diabetes is a chronic condition characterized by elevated blood sugar levels due to the body's inability to produce or properly utilize insulin. The growing incidence of diabetes is largely attributed to sedentary lifestyles and unhealthy diets rich in sugar and processed foods, which lead to obesity and insulin resistance. Insulin aspart addresses this rising prevalence by offering rapid-acting insulin that effectively manages blood sugar spikes after meals, thereby improving overall glucose control in diabetic patients. For example, in March 2025, a report by the Office for Health Improvement and Disparities, a UK government department, indicated that the prevalence of type 2 diabetes among adults aged 17 and over in England rose to 7.0% in March 2024, up from 6.8% in March 2023. This trend underscores how rising diabetes rates are fueling the demand for insulin aspart.
Companies operating in the insulin aspart market are increasingly focusing on developing innovative products, such as biosimilars, to offer more affordable options and expand access to high-quality insulin therapies. A biosimilar is a biologic medical product that closely resembles an already approved reference biologic and has no significant differences in terms of safety, purity, or efficacy. In November 2023, USV Pvt Ltd, an Indian pharmaceutical firm, introduced INSUQUICK, India's first biosimilar insulin aspart. This rapid-acting insulin analog was entirely developed and produced using indigenous technology and underwent a rigorous clinical program to meet global standards. The insulin pens are designed for precise dosing, featuring a clear scale and audible clicks. INSUQUICK is now available across metropolitan areas and tier I and II cities, aiming to enhance treatment accessibility for India's large diabetic population by offering a locally made, high-quality, and affordable insulin solution.
In March 2025, Biocon Biologics, a biopharmaceutical company based in India, partnered with Civica Inc. to improve the affordability and availability of insulin aspart in the United States. Under this collaboration, Biocon Biologics will supply the drug substance to Civica, which will handle domestic manufacturing and commercialization. This partnership seeks to meet the urgent need for cost-effective diabetes treatments in the U.S. Civica Inc. is a U.S.-based pharmaceutical company that focuses on producing and distributing insulin aspart.
Major players in the insulin aspart market are Sanofi S.A., AstraZeneca plc, Novo Nordisk A/S, Cipla Limited, Lupin Limited, Zhejiang Hisun Pharmaceutical Co Ltd., Biocon Limited, Amphastar Pharmaceuticals Inc., Civica Inc., Wockhardt Limited, Gulf Pharmaceutical Industries PSC (Julphar), GEROPHARM LLC, HEC Pharm Co Ltd., USV Private Limited, Aqlivia Private Limited, Gan & Lee Pharmaceuticals Co Ltd., GeneSys Biologics Private Limited, Biogenomics Limited, MJ Biopharma Private Limited, and Paras Biopharmaceuticals Finland Oy.
North America was the largest region in the insulin aspart market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in insulin aspart report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the insulin aspart market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The insulin aspart market consists of sales of rapid-acting insulin analogs, biosimilar insulin aspart formulations, pre-filled insulin pens, vial-based insulin solutions, and combination insulin products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Insulin Aspart Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on insulin aspart market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for insulin aspart ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The insulin aspart market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.